Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Apple Turns 50: From Garage Startup to AI Crossroads 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Britain Courts Anthropic Amid US Defense Department Dispute 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
NORCROSS, Ga., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Immucor, Inc., a global leader in transfusion and transplantation diagnostics, today announced that it will hold a conference call with debt investors on Tuesday, February 2, 2016, at 2:00 p.m. ET to discuss its fiscal 2016 second quarter results.
Interested debt investors and analysts should contact Immucor Investor Relations at [email protected] or 770-441-2051 for details.
About Immucor
Founded in 1982, Immucor is a global leader in transfusion and transplantation diagnostics that facilitate patient-donor compatibility. Our mission is to ensure that patients in need of blood, organs or stem cells get the right match that is safe, accessible and affordable. With the right match, we can transform a life together. For more information on Immucor, please visit our website at www.immucor.com.
CONTACT: Michele Howard 770-441-2051
